[go: up one dir, main page]

WO1998030231A9 - Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire - Google Patents

Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire

Info

Publication number
WO1998030231A9
WO1998030231A9 PCT/US1998/000449 US9800449W WO9830231A9 WO 1998030231 A9 WO1998030231 A9 WO 1998030231A9 US 9800449 W US9800449 W US 9800449W WO 9830231 A9 WO9830231 A9 WO 9830231A9
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
peptide
exendin
tfa
gly
Prior art date
Application number
PCT/US1998/000449
Other languages
English (en)
Other versions
WO1998030231A1 (fr
Filing date
Publication date
Priority to CA002277112A priority Critical patent/CA2277112C/fr
Priority to DE122007000044C priority patent/DE122007000044I2/de
Priority to AT98904545T priority patent/ATE304864T1/de
Priority to DE69831673.8T priority patent/DE69831673C5/de
Priority to JP53114798A priority patent/JP4798814B2/ja
Priority to EP98904545A priority patent/EP0996459B1/fr
Priority to AU62394/98A priority patent/AU739020B2/en
Application filed filed Critical
Publication of WO1998030231A1 publication Critical patent/WO1998030231A1/fr
Publication of WO1998030231A9 publication Critical patent/WO1998030231A9/fr
Priority to HK00104513A priority patent/HK1025252A1/xx
Priority to FR07C0031C priority patent/FR07C0031I2/fr
Priority to BE2007C038C priority patent/BE2007C038I2/fr
Priority to NL300281C priority patent/NL300281I2/nl
Priority to LU91342C priority patent/LU91342I2/fr

Links

Definitions

  • the present invention relates to methods for treating conditions or disorders which can be alleviated by reducing food intake comprising administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other compounds or compositions that affect satiety such as a leptin or an amylin agonist.
  • the methods are useful for treating conditions or disorders, in which the reduction of food intake is of value, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome.
  • the methods are also useful for lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects.
  • Pharmaceutical compositions for use in the methods of the invention are also disclosed. BACKGROUND
  • the following description summarizes information relevant to the present invention. It is not an admission that any of the information provided herein is prior art to the presently claimed invention, nor that any of the publications specifically or implicitly referenced are prior art to that invention.
  • Exendin Exendins are peptides that are found in the venom of the Gila-monster, a lizard found in Arizona, and the Mexican Beaded Lizard. Exendin-3 is present in the venom of Heloderma horridum, and exendin-4 is present in the venom of Heloderma suspectum (Eng, J. , et al . , J. Biol. Chem., 265:20259-62, 1990; Eng., J. , et al . , J. Biol. Chem., 267:7402-05, 1992).
  • the exendins have some sequence similarity to several members of the glucagon- like peptide family, with the highest homology, 53%, being to GLP-1 [7-36]NH 2 (Goke, et al . , J. Biol . Chem.. 268:19650- 55, 1993).
  • GLP-1 [7-36] NH 2 also known as proglucagon [78- 107] , has an insulinotropic effect, stimulating insulin secretion from pancreatic ⁇ -cells; GLP also inhibits glucagon secretion from pancreatic ⁇ -cells (Orskov, et al., Diabetes, 42:658-61, 1993; D'Alessio, et al . , J Clin.
  • GLP-1 is reported to inhibit gastric emptying (Williams B, et al . , J Clin Endocrinol Metab 81 (1): 327-32, 1996; Wettergren A, et al., Dig Pis Sci 38 (4): 665-73, 1993), and gastric acid secretion. (Schjoldager BT, et al . , Dig Pis Sci 34 (5): 703-8, 1989; O'Halloran DJ, et al . , J Endocrinol 126 (1): 169-73, 1990; Wettergren A, et al . , Dig Pis Sci 38 (4): 665-73, 1993).
  • GLP-1 [7-37] , which has an additional glycine residue at its carboxy terminus, also stimulates insulin secretion in humans (Orskov, et al . , Diabetes. 42:658-61, 1993).
  • a transmembrane G-protein adenylate- cyclase-coupled receptor believed to be responsible for the insulinotropic effect of GLP-1 is reported to have been cloned from a ⁇ -cell line (Thorens, Proc. Natl. Acad. Sci. USA 89:8641-45 (1992)).
  • Exendin-4 potently binds at GLP-1 receptors on insulin-secreting ⁇ TCl cells, at dispersed acinar cells from guinea pig pancreas, and at parietal cells from stomach; the peptide is also said to stimulate somatostatin release and inhibit gastrin release in isolated stomachs (Goke, et al . , J. Biol. Chem. 268:19650-
  • Exendin-3 and exendin-4 were reported to stimulate cAMP production in, and amylase release from, pancreatic acinar cells (Malhotra, R. , et al . , Regulatory Peptides .41 : 149-
  • exendin-3 and exendin-4 as insulinotrophic agents for the treatment of diabetes mellitus and the prevention of hyperglycemia has been proposed (Eng, U.S. Patent No. 5,424,286) .
  • C-terminally truncated exendin peptides such as exendin [9-39] , a carboxyamidated molecule, and fragments 3-39 through 9-39 have been reported to be potent and selective antagonists of GLP-1 (Goke, et al . , J.
  • Exendin [9-39] is said to block endogenous GLP-1 in vivo, resulting in reduced insulin secretion. Wang, et al . , J. Clin. Invest .. 95:417-21, 1995; D'Alessio, et al .
  • the receptor apparently responsible for the insulinotropic effect of GLP-1 has reportedly been cloned from rat pancreatic islet cell (Thorens, B., Proc. Natl. Acad. Sci. USA 89:8641-8645, 1992) . Exendins and exendin [9-39] are said to bind to the cloned GLP-1 receptor (rat pancreatic ⁇ -cell GLP-1 receptor (Fehmann HC, et al., Peptides 15 (3): 453-6, 1994) and human GLP-1 receptor (Thorens B, et al . , Diabetes 42 (11): 1678-82, 1993) .
  • exendin-4 is reportedly an agonist, i.e., it increases cAMP, while exendin [9-39] is identified as an antagonist, i.e., it blocks the stimulatory actions of exendin-4 and GLP-1.
  • Exendin [9-39] is also reported to act as an antagonist of the full length exendins, inhibiting stimulation of pancreatic acinar cells by exendin-3 and exendin-4 (Raufman, et al . , J. Biol. Chem. 266:2897-902, 1991; Raufman, et al . , J. Biol. Chem., 266:21432-37, 1992).
  • exendin [9-39] inhibits the stimulation of plasma insulin levels by exendin-4, and inhibits the somatostatin release-stimulating and gastrin release-inhibiting activities of exendin-4 and GLP-1 (Kolligs, F., et al . , Diabetes, 44:16-19, 1995; Eissele, et al., Life Sciences, 55:629-34, 1994).
  • Exendin [9-39] has been used to investigate the physiological relevance of central GLP-1 in control of food intake (Turton, M.D. et al . Nature 379:69-72, 1996).
  • GLP-1 administered by mtracerebroventricular injection inhibits food intake in rats.
  • This satiety-inducing effect of GLP-1 delivered ICV is reported to be inhibited by ICV injection of exendin [9-39] (Turton, supra) .
  • GLP-1 does not inhibit food intake in mice when administered by peripheral injection (Turton, M.D. , Nature 379:69-72, 1996; Bhavsar, S.P., Soc. Neurosci. Abstr. 21:460 (188.8), 1995).
  • the pathogenesis of obesity is believed to be multifactorial but the basic problem is that in obese subjects food intake and energy expenditure do not come into balance until there is excess adipose tissue.
  • the present invention concerns the surprising discovery that exendins and exendin agonists have a profound and prolonged effect on inhibiting food intake.
  • the present invention is directed to novel methods for treating conditions or disorders associated with hypernutrition, comprising the administration of an exendin, for example, exendin-3 [SEQ ID NO. 1: His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser] , or exendin-4 [SEQ ID NO.
  • the invention features a method of treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to the subject a therapeutically effective amount of an exendin or an exendin agonist .
  • an exendin agonist is meant a compound that mimics the effects of exendin on the reduction of food intake by binding to the receptor or receptors where exendin causes this effect.
  • Preferred exendin agonist compounds include those described in United States Provisional Patent Application Serial No. 60/055,404, entitled, “Novel Exendin Agonist Compounds,” filed August 8, 1997; United States Provisional Patent Application Serial No. 60/065,442, entitled, “Novel Exendin Agonist Compounds,” filed November 14, 1997; and United States Provisional Patent Application Serial No. 60/066,029, entitled, “Novel Exendin Agonist Compounds,” filed November 14, 1997; all of which enjoy common ownership with the present application and all of which are incorporated by this reference into the present application as though fully set forth herein.
  • condition or disorder which can be alleviated by reducing food intake is meant any condition or disorder in a subject that is either caused by, complicated by, or aggravated by a relatively high food intake, or that can be alleviated by reducing food intake.
  • Such conditions or disorders include, but are not limited to, obesity, diabetes, including Type II diabetes, eating disorders, and insulin- resistance syndrome .
  • the present invention provides a method for treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist .
  • Preferred exendin agonist compounds include those described in U.S. Provisional Patent Application Serial Nos. 60/055,404; 60/065,442; and 60/066,029, which have been incorporated by reference in the present application.
  • the subject is a vertebrate, more preferably a mammal, and most preferably a human.
  • the exendin or exendin agonist is administered parenterally, more preferably by injection. In a most preferred aspect, the injection is a peripheral injection.
  • about 10 ⁇ g-30 ⁇ g to about 5 mg of the exendin or exendin agonist is administered per day. More preferably, about 10-30 ⁇ g to about 2mg, or about 10-30 ⁇ g to about lmg of the exendin or exendin agonist is administered per day. Most preferably, about 30 ⁇ g to about 500 ⁇ g of the exendin or exendin agonist is administered per day.
  • the condition or disorder is obesity, diabetes, preferably Type II diabetes, an eating disorder, or insulin-resistance syndrome .
  • a method for reducing the appetite of a subject comprising administering to said subject an appetite- lowering amount of an exendin or an exendin agonist .
  • a method for lowering plasma lipids comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist .
  • the methods of the present invention may also be used to reduce the cardiac risk of a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist .
  • the exendin or exendin agonist used in the methods of the present invention is exendin-3.
  • said exendin is exendin-4.
  • exendin-4 (1-30) [SEQ ID NO 6 : His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly], exendin-4 (1-30) amide [SEQ ID NO 7 : His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn Gly Gly-NH 2 ] , exendin-4 (1-28) amide [SEQ ID NO 40: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Phe lie Glu Trp Leu Lys Asn-NH 2 ] , 1 Leu, 25 Phe exendin-4 amide [SEQ IP NO 9 : His Gly Glu Gly Thr Phe Thr Ser As
  • the exendins and exendin agonists may be administered separately or together with one or more other compounds and compositions that exhibit a long term or short-term satiety action, including, but not limited to other compounds and compositions that comprise an amylin agonist, cholecystokinin (CCK) , or a leptin (ob protein) .
  • Suitable amylin agonists include, for example, [ 25,28,29 Pro-] -human amylin (also known as "pramlintide, " and previously referred to as "AC-137") as described in "Amylin Agonist Peptides and Uses Therefor," U.S. Patent No.
  • CCK-8 CCK octopeptide
  • Leptin is discussed in, for example, Pelleymounter, M.A. , et al . Science 269:540-43 (1995); Halaas, J.L. , et al . Science 269:543-46 (1995); and Campfield, L.A., et al . Eur . J. Pharmac. 262:133-41 (1994).
  • a pharmaceutical composition for use m the treatment of conditions or disorders which can be alleviated by reducing food intake comprising a therapeutically effective amount of an exendin or exendin agonist m association with a pharmaceutically acceptable carrier.
  • the pharmaceutical composition comprises a therapeutically effective amount for a human subject.
  • the pharmaceutical composition may preferably be used for reducing the appetite of a subject, reducing the weight of a subject, lowering the plasma lipid level of a subject, or reducing the cardiac risk of a subject.
  • the pharmaceutical composition will preferably comprise a therapeutically effective amount of an exendin or exendin agonist to accomplish the desired effect in the subject.
  • compositions may further comprise one or more other compounds and compositions that exhibit a long-term or short-term satiety action, including, but not limited to other compounds and compositions that comprise an amylin agonist, CCK, preferably CCK-8, or leptin.
  • Suitable amylin agonists include, for example, [ 25,28 ' 29 Pro] - human amylin and salmon calcitonin.
  • the pharmaceutical composition comprises exendin-3. In another preferred aspect, the pharmaceutical composition comprises exendin-4.
  • compositions comprises a peptide selected from: exendin-4
  • exendin-4 (1-30) , exendin-4 (1-30) amide, exendin-4 (1-28) amide, 14 Leu, 25 Phe exendin-4 amide, 14 Leu, 25 Phe exendin-4 (1-28) amide, and 1 Leu, 22 Ala, 25 Phe exendin-4 (1-28) amide.
  • Figure 1 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 and GLP-1.
  • Figure 2 is a graphical depiction of the change of food intake in obese mice after intraperitoneal injection of exendin-4.
  • Figure 3 is a graphical depiction of the change of food intake in rats after intracerebroventricular injection of exendin-4
  • Figure 4 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-30) ("Compound 1") .
  • Figure 5 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-30) amide ("Compound 2”) .
  • Figure 6 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-28) amide ("Compound 3") .
  • Figure 7 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of 14 Leu, 25 Phe exendin-4 amide ("Compound 4").
  • Figure 8 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of 1 Leu, 25 Phe exendin-4 (1-28) amide ("Compound 5") .
  • Figure 9 is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of 14 Leu, 22 Ala, 2S Phe exendin-4 (1-28) amide ("Compound 6").
  • Figure 10 depicts the amino acid sequences for certain exendin agonist compounds useful in the present invention [SEQ IP NOS 9-39] .
  • Exendins and exendin agonists are useful as described herein in view of their pharmacological properties.
  • exendin agonists can be indicated by activity in the assays described below. Effects of exendins or exendin agonists on reducing food intake can be identified, evaluated, or screened for, using the methods described in the Examples below, or other methods known in the art for determining effects on food intake or appetite.
  • Exendin agonist compounds are those described in U.S. Provisional Application No. 60/055,404, including compounds of the formula (I) [SEQ ID NO. 3] :
  • Xaa x is His, Arg or Tyr;
  • Xaa 2 is Ser, Gly, Ala or Thr;
  • Xaa 3 is Asp or Glu;
  • Xaa 4 is Phe, Tyr or naphthylalanine;
  • Xaa 5 is Thr or Ser;
  • Xaa 6 is Ser or Thr;
  • Xaa 7 is Asp or Glu;
  • Xaa 8 is Leu, He, Val, pentylglycine or Met;
  • Xaa 9 is Leu, He, pentylglycine, Val or Met;
  • Xaa 10 is Phe, Tyr or naphthylalanine;
  • Xaa lx is He, Val, Leu, pentylglycine, tert-butylglycine or Met;
  • Xaa 12 is Glu or Asp;
  • Xaa 13 is Trp, Phe, Tyr,
  • N-alkyl groups for N-alkylglycine, N- alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms. Suitable compounds include those listed in Figure 10 having amino acid sequences of SEQ. ID. NOS. 9 to 39.
  • Preferred exendin agonist compounds include those wherein Xaa x is His or Tyr. More preferably Xaa x is His.
  • Preferred compounds include those wherein Xaa 13 is Trp or Phe .
  • Xaa 4 is Phe or naphthylalanine
  • Xaa u is He or Val
  • Xaa 14 , Xaa 15 , Xaa 16 and Xaa 17 are independently selected from Pro, homoproline, thioproline or N-alkylalanine.
  • N-alkylalanine has a N-alkyl group of 1 to about 6 carbon atoms.
  • Xaa 15 , Xaa 16 and Xaa 17 are the same amino acid reside.
  • Z is -NH 2 .
  • Xaa x is His or Tyr, more preferably His;
  • Xaa 2 is Gly;
  • Xaa 4 is Phe or naphthylalanine;
  • Xaa 9 is Leu, pentylglycine or Met;
  • Xaa 10 is Phe or naphthylalanine;
  • Xaa lx is He or Val;
  • Xaa 14 , Xaa 15 , Xaa 16 and Xaa 17 are independently selected from Pro, homoproline, thioproline or N-alkylalanine;
  • Xaa 18 is Ser or Tyr, more preferably Ser. More preferably Z is -NH 2 .
  • especially preferred compounds include those of formula (I) wherein: Xaa., is His or Arg; Xaa 2 is Gly; Xaa 3 is Asp or Glu,-. Xaa 4 is Phe or napthylalanine; Xaa 5 is Thr or Ser;
  • Especially preferred compounds include those having the amino acid sequence of
  • Xaa 9 is Leu, He, Val or pentylglycine, more preferably Leu or pentylglycine
  • Xaa 13 is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine.
  • Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/065,442, including compounds of the formula (II) [SEQ ID NO. 4]:
  • Xaa 2 Xaa 22 Xaa 23 Xaa,,, Xaa 25 Xaa 2e Xaa 27 Xaa 28 -Z,;
  • Xaa is His, Arg or Tyr
  • Xaa 2 is Ser, Gly, Ala or Thr;
  • Xaa 3 is Asp or Glu
  • Xaa 5 is Ala or Thr
  • Xaa 6 is Ala, Phe, Tyr or naphthylalanine
  • Xaa is Thr or Ser
  • Xaa is Ala, Ser or Thr;
  • Xaa 15 is Ala or Glu
  • Xaa i6 is Ala or Glu
  • Xaa,- is Ala or Glu
  • Xaa 19 is Ala or Val
  • Xaa 20 is Ala or Arg
  • Xaa 21 is Ala or Leu
  • Xaa 22 is Ala, Phe, Tyr or naphthylalanine;
  • Xaa, 3 is He, Val, Leu, pentylglycine, tert-butylglycine or Met;
  • Xaa 24 is Ala, Glu or Asp;
  • Xaa 25 is Ala, Trp, Phe, Tyr or naphthylalanine
  • Xaa 26 is Ala or Leu
  • Xaa,, is Ala or Lys
  • Xaa 2S is Ala or Asn
  • Z 1 is-OH
  • Xaa 3 , Xaa 36 , Xaa 37 and Xaa 38 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline,
  • N-alkylglycine N-alkylpentylglycine or
  • Z 2 is -OH or -NH 2 ; provided that no more than three of Xaa 3 , Xaa 5 , Xaa 6 , Xaa 8 , Xaa, 0 , Xaa, j , Xaa 12 , Xaa 13 , Xaa, 4 , Xaa 16 , Xaa 16 , Xaa 1 , Xaa 19 , Xaa,, Xaa,, Xaa 24 , Xaa,., Xaa, 6 , Xaa 2 , and Xaa 28 are Ala.
  • N-alkyl groups for N-alkylglycine, N- alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms.
  • Preferred exendin agonist compounds include those wherein Xaa x is His or Tyr. More preferably Xaa ⁇ is His.
  • Preferred compounds are those wherein Xaa 25 is Trp or Phe.
  • Preferred compounds are those where Xaa 6 is Phe or naphthylalanine; Xaa 22 is Phe or naphthylalanine and X a 23 is He or Val.
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from Pro, homoproline, thioproline and N-alkylalanine.
  • Z. is -NH 2 .
  • Z 2 is -NH 2 .
  • Xaa 2 is His or Tyr, more preferably His; Xaa 2 is Gly; Xaa 6 is Phe or naphthylalanine; Xaa 14 is
  • especially preferred compounds include those of formula (I) wherein: Xaa- !
  • Xaa 14 is Leu, He, Val or pentylglycine, more preferably Leu or pentylglycine
  • Xaa 25 is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine.
  • Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/066,029, including compounds of the formula (III) [SEQ ID NO. 5]:
  • Xaa Xaa, Xaa 3 Xaa 4 Xaa 5 Xaa 6 Xaa 7 Xaa 8 Xaa 9 Xaa 10 Xaa : ⁇ Xaa 12 Xaa 13 Xaa 14 Xaa 15 Xaa 16 Xaa 17 Ala Xaa 19 Xaa 20 Xaa,, Xaa,, Xaa 23 Xaa, 4 Xaa 25 Xaa, 6 Xaa,, Xaa 28 -Z ⁇ ; wherein
  • Xaa is His, Arg, Tyr, Ala, Norval, Val or Norleu;
  • Xaa is Ser, Gly, Ala or Thr;
  • Xaa 3 is Ala, Asp or Glu;
  • Xaa 4 is Ala, Norval, Val, Norleu or Gly;
  • Xaa 5 is Ala or Thr
  • Xaa 6 is Phe, Tyr or naphthylalanine ;
  • Xaa is Thr or Ser;
  • Xaa 9 is Ala, Ser or Thr;
  • Xaa 9 is Ala, Norval, Val, Norleu, Asp or Glu
  • Xaa 10 is Ala, Leu, He, Val, pentylglycine or Met
  • Xaa : is Ala or Ser
  • Xaa 12 is Ala or Lys
  • Xaa 13 is Ala or Gin
  • Xaa 14 is Ala, Leu, He, pentylglycine, Val or Met;
  • Xaa 15 is Ala or Glu;
  • Xaa 16 is Ala or Glu;
  • Xaa is Ala or Glu
  • Xaa 19 is Ala or Val
  • Xaa 20 is Ala or Arg
  • Xaa 21 is Ala or Leu
  • Xaa, is Phe, Tyr or naphthylalanine
  • Xaa, 3 is He, Val, Leu, pentylglycine, tert-butylglycine or Met;
  • Xaa 24 is Ala, Glu or Asp
  • Xaa 2E is Ala, Trp, Phe, Tyr or naphthylalanine; Xaa 26 is Ala or Leu;
  • Xaa 27 is Ala or Lys; Xaa 28 is Ala or Asn; Z x is -OH,
  • Gly Gly Xaa 31 Ser Ser Gly Ala Xaa 36 -Z 2
  • Gly Gly Xaa 31 Ser Ser Gly Ala Xaa 36 Xaa 37 -Z 2 ,
  • Gly Gly Xaa 31 Ser Ser Gly Ala Xaa 36 Xaa 37 Xaa 38 -Z, or Gly Gly Xaa 31 Ser Ser Gly Ala Xaa 36 Xaa 37 Xaa 38 Xaa 39 -Z 2 ;
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently
  • Z is -OH or -NH 2 ; provided that no more than three of Xaa 3 , Xaa 4 , Xaa 5 , Xaa 6 , aa ⁇ 7 , xaa ⁇ , xaa 2 g, xaa 2 - ⁇ , xaa,, xaac,, xaa 2 ⁇ , xaa, and xaa 8 are Ala; and provided also that, if Xaa x is His, Arg or Tyr, then at least one of Xaa 3 , Xaa 4 and Xaa 9 is Ala.
  • amino acid refers to natural amino acids, unnatural amino acids, and amino acid analogs, all in their D and L stereoisomers if their structure allow such stereoisomeric forms.
  • Natural amino acids include alanine (Ala) , arginine (Arg) , asparagine (Asn) , aspartic acid (Asp) , cysteine (Cys) , glutamine (Gin) , glutamic acid (Glu) , glycine (Gly) , histidine (His) , isoleucine (He) , leucine (Leu) , Lysine (Lys) , methionine (Met) , phenylalanine (Phe) , proline (Pro) , serine (Ser) , threonine (Thr) , typtophan (Trp) , tyrosine (Tyr) and valine (Val) .
  • Unnatural amino acids include, but are not limited to azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2- aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3- aminoisbutyric acid, 2-aminopimelic acid, tertiary- butylglycine, 2 , 4-diaminoisobutyric acid, desmosine, 2,2'- diaminopimelic acid, 2 , 3-diaminopropionic acid, N- ethylglycine, N-ethylasparagine, homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4- hydroxyproline, isodesmosine, allo-isoleucine, N- methylalanine, N-methylglycine, N-methyl
  • Amino acid analogs include the natural and unnatural amino acids which are chemically blocked, reversibly or irreversibly, or modified on their N-terminal amino group or their side-chain groups, as for example, methionine sulfoxide, methionine sulfone, S- (carboxymethyl) -cysteine , S- (carboxymethyl ) -cysteine sulfoxide and S- (carboxymethyl) -cysteine sulfone.
  • amino acid analog refers to an amino acid wherein either the C-terminal carboxy group, the N- terminal amino group or side-chain functional group has been chemically codified to another functional group.
  • aspartic acid- (beta-methyl ester) is an amino acid analog of aspartic acid
  • N-ethylglycine is an amino acid analog of glycine
  • alanine carboxamide is an amino acid analog of alanine.
  • amino acid residue refers to radicals having the structure: (1) -C(0)-R-NH-, wherein R typically is -CH(R')-, wherein R' is an amino acid side chain, typically H or a carbon containing substitutent ; or (2),
  • p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipecolic acid residues, respectively.
  • “lower” referred to herein in connection with organic radicals such as alkyl groups defines such groups with up to and including about 6, preferably up to and including 4 and advantageously one or two carbon atoms . Such groups may be straight chain or branched chain.
  • “Pharmaceutically acceptable salt” includes salts of the compounds described herein derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds are useful in both free base and salt form.
  • the following abbreviations stand for the following:
  • ACN or "CH 3 CN” refers to acetonitrile.
  • Boc , “tBoc” or “Tboc” refers to t-butoxy carbonyl .
  • DCC refers to N,N' -dicyclohexylcarbodiimide .
  • Fluorenylmethoxycarbonyl refers to fluorenylmethoxycarbonyl .
  • HBTU refers to 2- (lH-benzotriazol-1-yl) - 1,1,3,3, -tetramethyluronium hexaflurophosphate .
  • HOBt refers to 1-hydroxybenzotriazole monohydrate .
  • MeAla or “Nme” refers to N-methylalanine .
  • naph refers to naphthylalanine.
  • pG or pGly” refers to pentylglycine .
  • tBuG refers to tertiary-butylglycine .
  • ThioP or tPro refers to thioproline.
  • exendins and exendin agonists described herein may be prepared using standard solid-phase peptide synthesis techniques and preferably an automated or semiautomated peptide synthesizer.
  • an -N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N-methylpyrrolidinone or methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine .
  • the ⁇ -N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain.
  • a reagent such as trifluoroacetic acid or piperidine
  • Suitable N- protecting groups are well known in the art, with t- butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl (Fmoc) being preferred herein.
  • the solvents, amino acid derivatives and 4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, CA) .
  • the following side-chain protected amino acids may be purchased from Applied Biosystems,
  • Boc-Arg(Mts) Fmoc-Arg (Pmc) , Boc-Thr (Bzl) , Fmoc- Thr(t-Bu), Boc-Ser(Bzl) , Fmoc-Ser (t-Bu) , Boc-Tyr (BrZ) , Fmoc-Tyr (t-Bu) , Boc-Lys (Cl-Z) , Fmoc-Lys (Boc) , Boc-Glu(Bzl) , Fmoc-Glu(t-Bu) , Fmoc-His (Trt) , Fmoc- Asn(Trt) , and Fmoc-Gin (Trt) .
  • Boc-His may be purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, CA) .
  • Anisole, dimethylsulfide, phenol, ethanedithiol , and thioanisole may be obtained from Aldrich Chemical Company (Milwaukee, WI) . Air Products and Chemicals (Allentown, PA) supplies HF.
  • Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, PA) .
  • Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, CA) using the NMP/HOBt (Option 1) system and tBoc or Fmoc chemistry (see, Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer, Version 1.3B July 1, 1988, section 6, pp. 49- 70, Applied Biosystems, Inc., Foster City, CA) with capping. Boc-peptide-resins may be cleaved with HF (-5° C to 0° C, 1 hour) . The peptide may be extracted from the resin with alternating water and acetic acid, and the filtrates lyophilized.
  • an automatic peptide synthesizer Model 430A, Applied Biosystems Inc., Foster City, CA
  • NMP/HOBt Option 1
  • tBoc or Fmoc chemistry see, Applied Biosystems User'
  • the Fmoc-peptide resins may be cleaved according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12) . Peptides may be also be assembled using. an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville, Kentucky) .
  • Peptides may be purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system.
  • a C4 , C8 or C18 preparative column (lO ⁇ , 2.2 x 25 cm; Vydac, Hesperia, CA) may be used to isolate peptides, and purity may be determined using a C4 , C8 or C18 analytical column (5 ⁇ , 0.46 x 25 cm; Vydac).
  • Amino acid analyses may be performed on the Waters Pico Tag system and processed using the Maxima program.
  • Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115° C, 20-24 h) .
  • Hydrolysates may be derivatized and analyzed by standard methods (Cohen, et. al . , The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, MA (1989)).
  • Fast atom bombardment analysis may be carried out by M-Scan, Incorporated (West Chester, PA) .
  • Mass calibration may be performed using cesium iodide or cesium iodide/glycerol .
  • Plasma desorption ionization analysis using time of flight detection may be carried out on an Applied Biosystems Bio- Ion 20 mass spectrometer. Electrospray mass spectroscopy may be carried out on a VG- Trio machine .
  • Peptide compounds useful in the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, e.g., Sambrook et. al . , Molecular Cloning: A Laboratory Manual, 2d Ed. , Cold Spring Harbor (1989) .
  • Non-peptide compounds useful in the present invention may be prepared by art-known methods.
  • phosphate-containing amino acids and peptides containing such amino acids may be prepared using methods known in the art. See, e.g. , Bartlett and Landen, Biorg. Chem. 14:356-377 (1986).
  • the compounds described above are useful in view of their pharmacological properties.
  • the compounds of the invention possess activity as agents to reduce food intake. They can be used to treat conditions or diseases which can be alleviated by reducing food intake .
  • compositions useful in the invention may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) or nasal or oral administration.
  • parenteral including intravenous, intramuscular and subcutaneous
  • oral administration it will be convenient to provide an exendin or exendin agonist and another food-intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent, such as amylin, an amylin agonist, a CCK, or a leptin, in a single composition or solution for administration together.
  • a suitable administration format may best be determined by a medical practitioner for each patient individually. Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g.
  • compositions useful in the invention can be provided as parenteral compositions for injection or infusion. They can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, olive oil, or other acceptable carrier. Preferably, they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 3.0 to 8.0, preferably at a pH of about 3.5 to 5.0. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH buffering agents.
  • Useful buffers include for example, sodium acetate/acetic acid buffers.
  • a form of repository or "depot" slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery.
  • the desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes.
  • sodium chloride is preferred particularly for buffers containing sodium ions.
  • compositions can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and/or complexes thereof.
  • Pharmaceutically acceptable salts are non-toxic salts at the concentration at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical-chemical characteristics of the composition without preventing the composition from exerting its physiological effect. Examples of useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate the administration -of higher concentrations of the drug.
  • Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride , phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate.
  • Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.
  • acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.
  • Such salts may be prepared by, for example, reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.
  • Carriers or excipients can also be used to facilitate administration of the compound. Examples of carriers and excipients include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents.
  • the compositions or pharmaceutical composition can be administered by different routes including intravenously, intraperitoneal, subcutaneous, and intramuscular, orally, topically, transmucosally, or by pulmonary inhalation.
  • solutions of the above compositions may be thickened with a thickening agent such as methyl cellulose.
  • a thickening agent such as methyl cellulose.
  • They may be prepared in emulsified form, either water in oil or oil in water.
  • emulsifying agents including, for example, acacia powder, a non-ionic surfactant (such as a Tween) , or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g. , a Triton) .
  • compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures.
  • the selected components may be simply mixed in a blender or other standard device to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.
  • compositions will be provided in dosage unit form containing an amount of an exendin or exendin agonist, for example, exendin-3, and/or exendin-4, with or without another food intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent.
  • an exendin or exendin agonist for use in reducing food intake are those that suppress appetite at a desired level.
  • an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition, the blood sugar level and other factors.
  • the effective daily appetite-suppressing dose of the compounds will typically be in the range of about 10 to 30 ⁇ g to about 5 mg/day, preferably about 10 to 30 ⁇ g to about 2 mg/day and more preferably about 10 to 100 ⁇ g to about 1 mg/day, most preferably about 30 ⁇ g to about 500 ⁇ g/day, for a 70 kg patient, administered in a single or divided doses.
  • the exact dose to be administered is determined by the attending clinician and is dependent upon where the particular compound lies within the above quoted range, as well as upon the age, weight and condition of the individual. Administration should begin whenever the suppression of food intake, or weight lowering is desired, for example, at the first sign of symptoms or shortly after diagnosis of obesity, diabetes mellitus, or insulin- resistance syndrome.
  • Administration may be by injection, preferably subcutaneous or intramuscular. Orally active compounds may be taken orally, however dosages should be increased 5-10 fold.
  • the optimal formulation and mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the compounds will typically be used to .treat human subjects they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats. To assist in understanding the present invention, the following Examples are included.
  • mice All mice (NIH: Swiss mice) were housed in a stable environment of 22 ( ⁇ 2)° C, 60 ( ⁇ 10) % humidity and a 12:12 light :dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with ad libi tum access to food (Teklad: LM 485; Madison, WI) and water except as noted, for at least two weeks before the experiments.
  • mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 ⁇ l/kg) of either saline or exendin-4 at doses of 0.1, 1.0, 10 and 100 ⁇ g/kg and were immediately presented with a pre-weighed food pellet (Teklad LM 485) . The food pellet was weighed at 30-minute, 1-hr, 2-hr and 6- hr intervals to determine the amount of food eaten.
  • Figure 1 depicts cumulative food intake over periods of 0.5, 1, 2 and 6hr in overnight-fasted normal NIH: Swiss mice following ip injection of salme, 2 doses of GLP-1, or 4 doses of exendm-4. At doses up to lOO ⁇ g/kg, GLP-1 had no effect on food intake measured over any period, a result consistent with that previously reported (Bhavsar, S.P., et al., Soc. Neurosci. Abstr. 21:460 (188.8) (1995); and Turton, M.D., Nature, 379:69-72, (1996)).
  • exendm-4 injections potently and dose- dependently inhibited food intake.
  • the ED 50 for inhibition of food intake over 30 mm was l ⁇ g/kg, which is a level about as potent as amylm (ED S0 3.6 ⁇ g/kg) or the prototypical peripheral satiety agent, CCK (ED 50 0.97 ⁇ g/kg) as measured m this preparation.
  • CCK the prototypical peripheral satiety agent
  • EXAMPLE 2 Exendin Reduced the Food Intake of Obese M ce All mice (female ob/ob mice) were housed in a stable environment of 22 ( ⁇ 2)° C, 60 ( ⁇ 10) % humidity and a 12:12 light :dark cycle; with lights on at 0600. Mice were housed m groups of four in standard cages with ad libitum access to food (Teklad: LM 485) and water except as noted, for at least two weeks before the experiments.
  • mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 ⁇ l/kg) of either salme or exendm-4 at doses of 0.1, 1.0 and 10 ⁇ g/kg (female ob/ob mice) and were immediately presented with a pre-weighed food pellet (Teklad LM 485) . The food pellet was weighed at 30-minute, 1 -hr, 2-hr and 6-hr intervals to determine the amount of food eaten.
  • FIG. 2 depicts the effect of exendin-4 in the ob/ob mouse model of obesity.
  • the obese mice had a similar food intake-related response to exendin as the normal mice.
  • the obese mice were not hypersensitive to exendin, as has been observed with amylin and leptin (Young, A.A. , et al . , Program and Abstracts. 10th International Congress of Endocrinology, June 12-15, 1996 San Francisco, pg 419 (P2-58) ) .
  • mice All rats (Harlan Sprague-Dawley) were housed in a stable environment of 22 ( ⁇ 2)° C, 60 ( ⁇ 10)% humidity and a
  • mice All mice (NIH: Swiss mice) were housed in a stable environment of 22 ( ⁇ 2)° C, 60 ( ⁇ 10) % humidity and a 12:12 light: dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with ad libi tum access to food (Teklad: LM 485; Madison, WI) and water except as noted, for at least two weeks before the experiments . All experiments were conducted between the . hours of
  • mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 ⁇ l/kg) of either saline or test compound at doses of 1, 10, and 100 ⁇ g/kg and immediately presented with a food pellet (Teklad LM 485) . The food pellet was weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount of food eaten.
  • Figure 4 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight -fasted normal NIH: Swiss mice following ip injection of saline or exendin-4 (1-30) ("Compound 1") in doses of 1 , 10 and 100 ⁇ g/kg.
  • Figure 5 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH: Swiss mice following ip injection of saline or exendin-4 (1-30) amide ("Compound 2") in doses of 1 , 10 and 100 ⁇ g/kg.
  • Figure 6 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH: Swiss mice following ip injection of saline or exendin-4 (1-28) amide ("Compound 3") in doses of 1 , 10 and 100 ⁇ g/kg.
  • Figure 7 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or 14 Leu, 25 Phe exendin-4 amide ("Compound 4") in doses of 1, 10 and 100 ⁇ g/kg.
  • Figure 8 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH: Swiss mice following ip injection of saline or 14 Leu, 25 Phe exendin-4 (1-28) amide ("Compound 5") in doses of 1, 10 and 100 ⁇ g/kg.
  • Figure 9 depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr overnight-fasted normal NIH: Swiss mice following ip injection of salme or 14 Leu, 22 Ala, 25 Phe exendm-4 (1-28) amide ("Compound 6") in doses of 1, 10 and 100 ⁇ g/kg.
  • Double deprotection was required at positions Arg 20 , Val 19 and Leu 14 .
  • Final deprotection of the completed peptide resm was achieved using a mixture of t ⁇ ethylsilane (0.2 mL) , ethanedithiol (0.2 mL) , anisole (0.2 mL) , water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.)
  • the peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water) . Crude purity was about 55%.
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resm (Novabiochem, 0.55 mmole/g) using Fmoc-protected ammo acids (Applied Biosystems, Inc.), cleaved from the resm, deprotected and purified in a similar way to Example 5.
  • Used m analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA m ACN) .
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resm (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA in water) and
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • the above amidated peptide was assembled on 4-(2'-4'- dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal) of the growing peptide chain was achieved using piperidine.
  • Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' - ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • amidated peptide was assembled on 4- (2 ' - ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' - ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used .in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' - ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide was assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimetnoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resm (Novabiochem, 0.55 mmole/g) using Fmoc-protected ammo acids (Applied Biosystems, Inc. ) , cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' - ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • the above-identified peptide is assembled on 4-(2'- 4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc. ) , cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc. ) , cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent 3 (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc. ) , cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' - ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Ecample 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • Peptides having the sequences of SEQ ID NOS. 7, 40- 61, 68-75, 78-80 and 87-96 are assembled on the so called Wang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g) ) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • the above amidated peptide was assembled on 4-(2'-4'- dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal) of the growing peptide chain was achieved using piperidine.
  • Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4 _ (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • EXAMPLE 117 Preparation of Peptide having SEP ID NP. 117 Ala Gly Asp Gly Thr Phe Ser Ser Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Phe He Glu Trp Leu Lys Asn-NH, [SEQ. ID. ⁇ G. 117]
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptiden is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • EXAMPLE 134 Preparation of Peptide having SEQ ID NO. 134 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala Leu Glu Glu Glu Ala Val Arg Leu Phe He Glu Phe Leu Lys Asn-NH 2 [SEQ. ID. NO. 134]
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • EXAMPLE 168 Preparation of Peptide having SEQ ID NO. 168 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Leu Glu Glu Glu Ala Val Arg Leu Phe He Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Pro-NH 2 [SEQ. ID. NO.
  • amidated peptide is assembled on 4_ (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • EXAMPLE 181 Preparation of Peptide having SEQ ID NO. 181 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gin Met Glu Glu Glu Ala Val Arg Leu Phe He Glu Trp Leu Lys Asn Gly Gly tPro Ser Ser Gly Ala tPro tPro tPro-NH 2 [SEQ. ID. NO. 181]
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Double couplings are required at residues 37,36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amdiated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100.
  • Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .
  • amidated peptide is assembled on 4- (2 ' -4 ' -dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied
  • C-terminal carboxylic acid peptides corresponding to the above C-terminal amide sequences for Peptides having SEQ ID NOS. 100-166, 172-177, 179-180 and 185-188 are assembled on the so called Wang resin (p- alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to that described in Example 100.
  • EXAMPLE 190 Preparation of C-terminal carboxylic acid peptides corresponding to the above C-terminal amide sequences for Peptides having SEQ ID NOS. 167-171, 178 and 181-184.
  • C-terminal carboxylic acid eptides corresponding to amidated SEQ ID NOS. 167-171, 178 and 181-184 are assembled on the 2-chlorotritylchloride resin (200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g)) using Fmoc- protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to that described in Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN) .

Abstract

L'invention concerne des procédés visant à traiter des états ou des troubles pouvant être atténués par une réduction de la consommation alimentaire. Lesdits procédés comprennent l'administration d'une dose efficace d'une exendine ou de son agoniste, seule ou en combinaison avec d'autres composés ou compositions qui jouent un rôle sur la satiété. Ces procédés sont utiles pour traiter des états ou des troubles, comme l'obésité, le diabète de type II, les troubles alimentaires et le syndrome insulinorésistant. Ces procédés sont également utiles pour faire diminuer le taux de glucose et de lipides dans le plasma, pour réduire les risques cardiaques, réduire l'appétit et faire perdre du poids à certains sujets. L'invention concerne également des compositions pharmaceutiques à utiliser dans le cadre desdits procédés.
PCT/US1998/000449 1997-01-07 1998-01-07 Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire WO1998030231A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU62394/98A AU739020B2 (en) 1997-01-07 1998-01-07 Use of exendins and agonists thereof for the reduction of food intake
AT98904545T ATE304864T1 (de) 1997-01-07 1998-01-07 Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
DE69831673.8T DE69831673C5 (de) 1997-01-07 1998-01-07 Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
JP53114798A JP4798814B2 (ja) 1997-01-07 1998-01-07 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
EP98904545A EP0996459B1 (fr) 1997-01-07 1998-01-07 Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
CA002277112A CA2277112C (fr) 1997-01-07 1998-01-07 Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
DE122007000044C DE122007000044I2 (de) 1997-01-07 1998-01-07 Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
HK00104513A HK1025252A1 (en) 1997-01-07 2000-07-21 Use of exendins and agonists thereof for the reduction of food intake.
BE2007C038C BE2007C038I2 (en) 1997-01-07 2007-05-16 Use of exendins and agonists thereof for the reduction of food intake
FR07C0031C FR07C0031I2 (fr) 1997-01-07 2007-05-16 Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
NL300281C NL300281I2 (nl) 1997-01-07 2007-05-18 Exenatide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
LU91342C LU91342I2 (fr) 1997-01-07 2007-05-18 Byetta-exénatide

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US3490597P 1997-01-07 1997-01-07
US60/034,905 1997-01-07
US5540497P 1997-08-08 1997-08-08
US60/055,404 1997-08-08
US6544297P 1997-11-14 1997-11-14
US6602997P 1997-11-14 1997-11-14
US60/065,442 1997-11-14
US60/066,029 1997-11-14

Publications (2)

Publication Number Publication Date
WO1998030231A1 WO1998030231A1 (fr) 1998-07-16
WO1998030231A9 true WO1998030231A9 (fr) 1998-11-12

Family

ID=27488253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/000449 WO1998030231A1 (fr) 1997-01-07 1998-01-07 Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire

Country Status (16)

Country Link
US (10) US6956026B2 (fr)
EP (2) EP1629849B2 (fr)
JP (1) JP4798814B2 (fr)
AT (1) ATE304864T1 (fr)
AU (1) AU739020B2 (fr)
BE (1) BE2007C038I2 (fr)
CA (1) CA2277112C (fr)
DE (2) DE69831673C5 (fr)
DK (2) DK0996459T3 (fr)
ES (2) ES2425559T5 (fr)
FR (1) FR07C0031I2 (fr)
HK (1) HK1025252A1 (fr)
LU (1) LU91342I2 (fr)
NL (1) NL300281I2 (fr)
PT (1) PT1629849E (fr)
WO (1) WO1998030231A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles

Families Citing this family (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2257119A1 (fr) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Analogues exendine, procedes permettant de les preparer et medicaments les contenant
AU4063697A (en) 1996-08-08 1998-02-25 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
DE69732572T2 (de) * 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US20040022807A1 (en) * 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
NZ502592A (en) * 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
EP1938831A1 (fr) * 1997-08-08 2008-07-02 Amylin Pharmaceuticals, Inc. Nouveaux composants d'agoniste d'exendine
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
EP1941900A1 (fr) * 1997-11-14 2008-07-09 Amylin Pharmaceuticals, Inc. Nouveaux composants d'agoniste d'exendine
AU2003200129B2 (en) * 1997-11-14 2006-06-22 Amylin Pharmaceuticals, Llc Novel Exendin Agonist Compounds
AU2006225176B2 (en) * 1997-11-14 2009-01-08 Amylin Pharmaceuticals, Llc Novel exendin agonist compounds
EP1938830A1 (fr) * 1997-11-14 2008-07-02 Amylin Pharmaceuticals, Inc. Nouveaux composants d'agoniste d'exendine
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
DK1032587T4 (da) * 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
AU757748B2 (en) * 1997-11-14 2003-03-06 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
EP1609478A1 (fr) 1999-01-14 2005-12-28 Amylin Pharmaceuticals, Inc. formulations de peptides agonistes de l'exendine
WO2000041548A2 (fr) 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Methodes de suppression du glucagon
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1175443A1 (fr) 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Exendines modifiees et agonistes de l'exendine
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (fr) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
DE60105547T3 (de) * 2000-01-10 2014-12-31 Amylin Pharmaceuticals, Llc Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
EP1634605A3 (fr) * 2000-03-08 2006-10-11 Novo Nordisk A/S traitement de la dyslipidémie chez un patient souffrant de diabète de type 2
US8273713B2 (en) 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
US20090281032A1 (en) * 2001-03-01 2009-11-12 Peter Raymond Flatt Modified CCK peptides
DE60228972D1 (de) * 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
PL205971B1 (pl) * 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
WO2003059378A2 (fr) * 2001-12-29 2003-07-24 Novo Nordisk A/S Utilisation combinee d'un compose glp-1 et d'un autre medicament pour traiter la dyslipidemie
WO2003057244A2 (fr) * 2002-01-08 2003-07-17 Amylin Pharmaceuticals, Inc. Utilisation d'agonistes d'amyline en vue de la modulation de triglycerides
JP4733922B2 (ja) * 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
AU2003243929B2 (en) 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
KR20050083713A (ko) 2002-10-02 2005-08-26 질랜드 파마 에이/에스 안정화된 엑센딘-4 화합물
AU2003286472A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US20060189520A1 (en) * 2002-10-22 2006-08-24 Brand Stephen J Treatment of diabetes
WO2004050115A2 (fr) * 2002-12-03 2004-06-17 Novo Nordisk A/S Polytherapie mettant en oeuvre des exendines et des thiazolidinediones
WO2004052390A1 (fr) * 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methodes et compositions de traitement du syndrome stein-leventhal
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1631308B1 (fr) * 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines
EP1663289A2 (fr) * 2003-08-29 2006-06-07 Amylin Pharmaceuticals, Inc. Procedes pour traiter ou ameliorer des maladies et des troubles associes a la ghreline
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
WO2005046716A1 (fr) * 2003-11-13 2005-05-26 Novo Nordisk A/S Compositions pharmaceutiques solubles destinées à l'administration parentérale comprenant un peptide glp-1 et un peptide d'insuline à temps d'action de courte durée, utiles pour le traitement du diabète et de la boulimie
PL1687019T3 (pl) 2003-11-20 2018-05-30 Novo Nordisk A/S Formulacje peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniach do wstrzykiwań
ATE498404T1 (de) * 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
IN2012DN03921A (fr) * 2004-02-11 2015-09-04 Amylin Pharmaceuticals Inc
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8114958B2 (en) 2004-02-11 2012-02-14 Amylin Pharmaceuticals, Inc. Amylin family peptides
EA011168B1 (ru) 2004-04-23 2009-02-27 Конджачем Биотекнолоджис Инк. Способ очистки конъюгатов альбумина
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
WO2005120492A1 (fr) * 2004-06-11 2005-12-22 Novo Nordisk A/S Remede contre l'obesite induite par les medicaments au moyen d'agonistes glp-1
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
AU2005305036B2 (en) * 2004-11-01 2011-03-10 Amylin Pharmaceuticals, Llc Treatment of obesity and related disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7393827B2 (en) * 2004-12-30 2008-07-01 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring β-cell mass and function
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (fr) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes selectionnables
EA011653B1 (ru) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Аналоги и гибридные полипептиды gip с избираемыми свойствами
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US7452868B2 (en) * 2005-03-11 2008-11-18 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
US7671023B2 (en) * 2005-03-31 2010-03-02 Amylin Pharmaceuticals, Inc. Amylin agonist for treating depression, anxiety disorder and schizophrenia
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
HUE045165T2 (hu) * 2005-08-19 2019-12-30 Amylin Pharmaceuticals Llc Exendin diabetes kezelésére és testtömeg csökkentésére
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
EP1954313A1 (fr) * 2005-11-01 2008-08-13 Amylin Pharmaceuticals, Inc. Traitement de l'obesite et de troubles associes
WO2007055743A2 (fr) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Procédés pour traiter l'obésité et des troubles associés
WO2007053946A1 (fr) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Procede de traitement du diabete et/ou de l'obesite en reduisant les effets secondaires nauseeux au moyen d'un peptide insulinotrope conjugue a de l'albumine
CN101316646B (zh) * 2005-11-29 2011-09-21 可隆株式会社 编织物增强的复合空心纤维膜
WO2007071068A1 (fr) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Procede de production de conjugues d'albumine preformes et agent therapeutique
CA2652907A1 (fr) * 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Compositions et methodes destinees au traitement du diabete
JP5102833B2 (ja) * 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション エキセンディン融合タンパク質
US8501693B2 (en) * 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
WO2008019143A2 (fr) * 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc Utilisation d'exendines et d'agonistes d'exendines et d'agonistes du récepteur glp-1 pour modifier la dimension de particule et la composition de sous-classe de lipoprotéines
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
CN101505594A (zh) * 2006-08-17 2009-08-12 维尔斯达医疗公司 代谢紊乱的组合治疗
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2057189B1 (fr) * 2006-08-25 2013-03-06 Novo Nordisk A/S Composés d'exendine-4 acylée
KR100872304B1 (ko) * 2006-11-28 2008-12-05 주식회사 코오롱 편물로 보강된 복합 중공사막
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2219664A1 (fr) * 2007-11-14 2010-08-25 Amylin Pharmaceuticals, Inc. Procédés de traitement de l'obésité et de maladies et de troubles associés à l'obésité
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
CA2726861C (fr) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
EP2259791A2 (fr) * 2008-03-05 2010-12-15 Tel HaShomer Medical Research Infrastructure and Services Ltd. Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
WO2009143285A2 (fr) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendines pour diminuer le cholestérol et les triglycérides
WO2009158412A2 (fr) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Libération lente d'exenatide et autres polypeptides
CA2729139C (fr) 2008-06-25 2016-07-26 Endo Pharmaceuticals Solutions Inc. Implant d'octreotide comportant un agent de liberation
WO2010010555A2 (fr) * 2008-07-21 2010-01-28 Transpharma Medical Ltd. Système transdermique de délivrance prolongée d'incrétines et de peptides mimétiques de l'incrétine
PT2341905T (pt) 2008-09-04 2020-07-27 Amylin Pharmaceuticals Inc Formulações de libertação sustentada utilizando transportadores não aquosos
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9238878B2 (en) * 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
WO2010138671A1 (fr) 2009-05-28 2010-12-02 Amylin Pharmaceuticals, Inc. Composés agonistes du récepteur glp-1 pour amélioration du sommeil
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
EP2496249B1 (fr) * 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Agoniste du récepteur du glp-1 pour l'utilisation dans le traitement de l'apnée obstructive du sommeil
HUE038147T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland GLP-1 agonistát, inzulint és metionint tartalmazó gyógyászati készítmény
DE102010011919A1 (de) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
WO2011058082A1 (fr) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Composition pharmaceutique comprenant un agoniste de glp-1 et de la méthionine
JP5892940B2 (ja) 2009-11-25 2016-03-23 アリスジェン ソシエテ アノニム クラウン化合物及び／又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
CN102100912B (zh) * 2009-12-16 2015-04-22 上海蓝心医药科技有限公司 一种给药组合物及其制备和使用方法
EP2555791B1 (fr) 2010-04-09 2017-11-01 Sinai Health System Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012028172A1 (fr) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Utilisation de lixisenatide pour fabrication de médicament pour traitement du diabète sucré de type 2
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2621538B1 (fr) 2010-09-28 2015-12-16 Amylin Pharmaceuticals, LLC Polypeptides génétiquement modifiés ayant une durée d'action renforcée
WO2012088157A2 (fr) 2010-12-22 2012-06-28 Amylin Pharmaceuticals, Inc. Agonistes du récepteur de glp-1 pour une transplantation de cellules d'îlot
EP2663647A4 (fr) 2011-01-14 2015-08-19 Redwood Bioscience Inc Immunoglobulines polypeptidiques à marquage aldéhydique et leur méthode d'utilisation
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2828346C (fr) 2011-03-01 2021-01-26 Synergy Pharmaceuticals Inc. Procede de preparation d'agonistes du guanylate cyclase c
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2714069A4 (fr) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc Conjugués de deux hormones longue durée
ES2634716T3 (es) 2011-05-31 2017-09-28 Celgene International Ii Sàrl Nuevos estabilizantes y moduladores del receptor GLP-1
EP2729493B1 (fr) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
EP2729481B1 (fr) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Polypeptides génétiquement modifiés ayant une durée d'action accrue avec une immunogénéicité réduite
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US20130096059A1 (en) 2011-10-04 2013-04-18 Jens Stechl Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
HUE028568T2 (en) 2011-10-04 2016-12-28 Sanofi Aventis Deutschland For use in the treatment of constriction and / or obstruction of the lysine senate and pancreatic duct system
US9259477B2 (en) 2011-11-03 2016-02-16 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
KR20140107340A (ko) 2011-12-12 2014-09-04 레셉토스, 인코포레이티드 당뇨병과 같은 치료를 위한 glp-1 수용체 조절제로서 작용하는 4 개의 사이클을 포함하는 카르복실산 유도체
CN104583234A (zh) 2012-06-14 2015-04-29 赛诺菲 毒蜥外泌肽-4肽类似物
UA117103C2 (uk) 2012-07-23 2018-06-25 Зіленд Фарма А/С Сполука, яка має активність агоніста глюкагону
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EA031428B1 (ru) 2012-12-21 2018-12-28 Санофи Функционализированные производные эксендина-4
KR101581497B1 (ko) 2013-01-24 2015-12-30 강원대학교산학협력단 인삼열매 추출물을 포함하는 파킨슨병과 알츠하이머병의 예방 또는 치료용 조성물
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
EP2968471B1 (fr) 2013-03-01 2017-07-19 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Peptides destinés à être utilisés dans le traitement topique de maladies neurodégénératives rétiniennes, en particulier dans les stades précoces de la rétinopathie diabétique et d'autres maladies rétiniennes dans lesquelles la neurodégénérescence joue un rôle essentiel
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
JP6573604B2 (ja) 2013-06-11 2019-09-11 セルジーン インターナショナル ツー エスエーアールエル 新規なｇｌｐ−１レセプターモジュレーター
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014336098B2 (en) 2013-10-17 2018-05-10 Boehringer Ingelheim International Gmbh Acylated glucagon analogues
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
WO2015067715A2 (fr) 2013-11-06 2015-05-14 Zealand Pharma A/S Composés agonistes doubles de gip et glp-1 et procédés associés
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
EP3080152A1 (fr) 2013-12-13 2016-10-19 Sanofi Analogues peptidiques de l'exendine 4 non acylés
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (fr) 2013-12-13 2018-08-01 Sanofi Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015104310A1 (fr) 2014-01-09 2015-07-16 Sanofi Formulations pharmaceutiques stabilisées d'insuline asparte
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
CA2932875A1 (fr) 2014-01-09 2015-07-16 Sanofi Formulations pharmaceutiques stabilisees sans glycerol d'analogues de l'insuline et/ou de derives de l'insuline
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EA032525B1 (ru) 2014-07-25 2019-06-28 Селджин Интернэшнл Ii Сарл Модуляторы рецептора glp-1
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
CN107207483B (zh) 2014-08-29 2020-10-30 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX381640B (es) 2014-10-29 2025-03-04 Zealand Pharma As Metodos y compuestos agonistas de gip.
KR102497644B1 (ko) 2014-12-10 2023-02-08 리셉토스 엘엘씨 Glp-1 수용체 조절제
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
BR112017019170A2 (pt) 2015-03-09 2018-07-10 Intekrin Therapeutics, Inc. métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
DK3297653T3 (da) 2015-05-22 2021-10-18 Univ Leland Stanford Junior Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017058482A1 (fr) * 2015-10-01 2017-04-06 Schlumberger Technology Corporation Amortissement actif pour outils de diagraphie par résonance magnétique nucléaire (rmn)
KR102686073B1 (ko) 2015-10-14 2024-07-17 엑스-써마 인코포레이티드 얼음 결정 형성을 감소시키기 위한 조성물 및 방법
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
EP3468576B1 (fr) * 2016-04-15 2023-06-07 Syracuse University Amélioration d'un médicament peptidique utilisant des conjugués de vitamine b12 et d'un substrat de liaison de l'haptocorrine
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
CA3024479A1 (fr) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Polypeptides selectifs du recepteur du glucagon et methodes pour les employer
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018057977A1 (fr) 2016-09-23 2018-03-29 Delpor, Inc. Compositions stables pour composés mimétiques de l'incrétine
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
BR112019010236A2 (pt) 2016-11-21 2019-08-20 Eiger Biopharmaceuticals Inc formulações tamponadas de exendina (9-39)
EP3551202B1 (fr) 2016-12-06 2024-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'amélioration de l'efficacité de médicaments à base d'incrétine chez les sujets en ayant besoin
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
CN118903385A (zh) 2017-08-24 2024-11-08 诺和诺德股份有限公司 Glp-1组合物及其用途
US11028123B2 (en) 2018-04-10 2021-06-08 Sanofi-Aventis Deutschland Gmbh Capping of unprotected amino groups during peptide synthesis
MX2020010716A (es) 2018-04-10 2021-03-09 Sanofi Aventis Deutschland Metodo para escindir de la fase solida peptidos unidos a una fase solida.
TW202033516A (zh) 2018-11-20 2020-09-16 義大利商Ｔｅｓ製藥（股份）責任有限公司 α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
MX2021010737A (es) 2019-03-08 2021-09-28 Amgen Inc Terapia de combinacion por factor de diferenciacion del crecimiento 15.
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
WO2024123812A1 (fr) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Protéines de fusion pour le traitement de maladies cardiométaboliques

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
JPH04504246A (ja) 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
KR0154880B1 (ko) 1992-06-15 1998-10-15 피터 알.셰어러 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
ZA946881B (en) 1993-09-07 1995-10-30 Amylin Pharmaceuticals Inc Methods for treating gastrointestinal motility
CA2171281C (fr) 1993-09-09 1998-12-29 Romeo Rang Compositions immunomodulatrices provenant de la bile
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1996006626A1 (fr) * 1994-08-26 1996-03-07 Lee Nancy M Procede analgesique utilisant des analogues de dynorphine tronques au niveau de la terminaison n
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5641425A (en) * 1994-09-08 1997-06-24 Multiform Desiccants, Inc. Oxygen absorbing composition
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
PL324284A1 (en) * 1995-06-30 1998-05-11 Lilly Co Eli Methods of treating diabetes
SE9600608L (sv) 1996-02-19 1997-02-17 Kavlugnt Ab Kopplingsanordning för sammankoppling av ett arbetsredskap till en arbetsmaskin; både mekanisk hopkoppling och snabbkoppling av hydraullikkopplingarna
CA2257119A1 (fr) 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Analogues exendine, procedes permettant de les preparer et medicaments les contenant
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
AU4050797A (en) 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU4063697A (en) * 1996-08-08 1998-02-25 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US5830904A (en) * 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
NZ502592A (en) 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
CA2299397A1 (fr) 1997-12-12 1999-06-24 Warner-Lambert Company Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6783942B2 (en) * 1998-10-08 2004-08-31 Uab Research Foundation Isolated polynucleotide associated with type II diabetes mellitus and methods of use thereof
US6326396B1 (en) 1998-11-20 2001-12-04 Alteon, Inc. Glucose and lipid lowering compounds
EP1609478A1 (fr) * 1999-01-14 2005-12-28 Amylin Pharmaceuticals, Inc. formulations de peptides agonistes de l'exendine
US6153432A (en) * 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
EP1175443A1 (fr) 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Exendines modifiees et agonistes de l'exendine
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
DE60105547T3 (de) 2000-01-10 2014-12-31 Amylin Pharmaceuticals, Llc Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
US6608038B2 (en) * 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles

Similar Documents

Publication Publication Date Title
EP0996459B1 (fr) Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
WO1998030231A9 (fr) Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
US7442680B2 (en) Inotropic and diuretic effects of GLP-1 and GLP-1 agonists
US8759291B2 (en) Methods of treatment using exendin peptides or GLP-1 peptides
EP1246638B2 (fr) Utilisation d'exendines et d'agonistes de ces dernieres pour traiter l'hypertriglyceridemie
US20090029913A1 (en) Novel exendin agonist compounds
US20080119393A1 (en) Novel exendin agonist compounds
AU784488C (en) Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia